Thryv Therapeutics

SGK1-inhibitor cardiometabolic therapeutics

Privately held: no public share price · Canada

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Serum/glucocorticoid-regulated kinase 1 (SGK1)Small molecule
Heart Failure

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
THRV-1268Phase 2/3Long QT Syndrome (LQTS) 2
Est. primary completion 2027-06-30 · NCT07277582 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.